Abstract
Agmatine is an endogenous brain metabolite, decarboxylated arginine, which has neuroprotective properties when injected intraperitoneally (i.p.) into rat pups following hypoxic-ischemia. A previous screen for compounds based on rat brain lysates containing agmatinase with assistance from computational chemistry, led to piperazine-1-carboxamidine as a putative agmatinase inhibitor. Herein, the neuroprotective properties of piperazine-1-carboxamidine are described both in vitro and in vivo. Organotypic entorhinal-hippocampal slices were firstly prepared from 7-day-old rat pups and exposed in vitro to atmospheric oxygen depletion for 3 h. Upon reoxygenation, the slices were treated with piperazine-1-carboxamidine or agmatine (50 μg/ml agents), or saline, and 15 h later propidium iodine was used to stain. Piperazine-1-carboxamidine or agmatine produced substantial in vitro protection compared to post-reoxygenated saline-treated controls. An in vivo model involved surgical right carotid ligation followed by exposure to hypoxic-ischemia (8 % oxygen) for 2.5 h. Piperazine-1-carboxamidine at 50 mg/kg i.p. was given 15 min post-reoxygenation and continued twice daily for 3 days. Cortical agmatine levels were elevated (+28.5 %) following piperazine-1-carboxamidine treatment with no change in arginine or its other major metabolites. Histologic staining with anti-Neun monoclonal antibody also revealed neuroprotection of CA1-3 layers of the hippocampus. Until endpoint at 22 days of age, no adverse events were observed in treated pups’ body weights, rectal temperatures, or prompted ambulation. Piperazine-1-carboxamidine therefore appears to be a neuroprotective agent of a new category, agmatinase inhibitor.
Similar content being viewed by others
References
Askalany A, Yamakura T, Petrenko A, Kohno T, Sakimura K, Baba H (2005) Effect of agmatine on heteromeric N-methyl-d-aspartate receptor channels. Neurosci Res 52:387–392
Bernstein HG, Derst C, Stich C, Pruss H, Peters D, Krauss M, Bogerts B, Veh RW, Laube G (2011) The agmatine-degrading enzyme agmatinase: a key to agmatine signaling in rat and human brain? Amino Acids 40:453–465
Bernstein HG, Stich C, Jager K, Dobrowolny H, Wick M, Steiner J, Veh R, Bogerts B, Laube G (2012) Agmatinase, an inactivator of the putative endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders. Neuropharmacology 62:237–246
Betancourt L, Rada P, Paredes D, Hernandez L (2012) In vivo monitoring of cerebral agmatine by microdialysis and capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 880:58–65
Brown J, Achille N, Neafsey EJ, Collins MA (2009) Binge ethanol-induced neurodegeneration in rat organotypic brain slice cultures: effects of PLA2 inhibitor mepacrine and docosahexaenoic acid (DHA). Neurochem Res 34:260–267
Calis U, Finch JR, Soltis EE, Digenis GA (1994) Synthesis of novel aminopropylguanidine derivatives with potential antihypertensive activity. Pharm Res 11:1211–1215
Coleman CS, Hu G, Pegg AE (2004) Putrescine biosynthesis in mammalian tissues. Biochem J 379:849–855
Demady DR, Jianmongkol S, Vuletich JL, Bender AT, Osawa Y (2001) Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol Pharmacol 59:24–29
Demehri S, Homayoun H, Honar H, Riazi K, Vafaie K, Roushanzamir F, Dehpour A (2003) Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 45:534–542
Feng Y, LeBlanc M (2003) Effect of agmatine on the time course of brain inflammatory cytokines after injury in rat pups. Ann N Y Acad Sci 1009:152–156
Feng Y, Piletz JE, Leblanc MH (2002) Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 52:606–611
Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ (1996) Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 316:247–249
Gilad GM, Salame K, Rabey JM, Gilad VH (1996) Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 58:41–46
Goracke-Postle CJ, Nguyen HO, Stone LS, Fairbanks CA (2006) Release of tritiated agmatine from spinal synaptosomes. Neuroreport 17:13–17
Goracke-Postle CJ, Overland AC, Stone LS, Fairbanks CA (2007) Agmatine transport into spinal nerve terminals is modulated by polyamine analogs. J Neurochem 100:132–141
Gorbatyuk OS, Milner TA, Wang G, Regunathan S, Reis DJ (2001) Localization of agmatine in vasopressin and oxytocin neurons of the rat hypothalamic paraventricular and supraoptic nuclei. Exp Neurol 171:235–245
Halaris A, Piletz J (2007) Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 21:885–900
He H, Liu M, Zheng Z, Liu Y, Xiao J, Su R, Hu C, Li J, Li S (2006) Synthesis and analgesic activity evaluation of some agmatine derivatives. Molecules 11:393–402
Holmes KH, Bilkey DK, Laverty R, Goddard GV (1990) The N-methyl-d-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures. Brain Res 506:227–235
Hong S, Kim CY, Lee JE, Seong GJ (2009) Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha-induced apoptosis. Life Sci 84:28–32
Horyn O, Luhovyy B, Lazarow A, Daikhin Y, Nissim I, Yudkoff M, Nissim I (2005) Biosynthesis of agmatine in isolated mitochondria and perfused rat liver: studies with 15N-labelled arginine. Biochem J 388:419–425
Huang MJ, Regunathan S, Botta M, Lee K, McClendon E, Yi GB, Pedersen ML, Berkowitz DB, Wang G, Travagli M, Piletz JE (2003) Structure-activity analysis of guanidine group in agmatine for brain agmatinase. Ann N Y Acad Sci 1009:52–63
Iyo AH, Zhu MY, Ordway GA, Regunathan S (2006) Expression of arginine decarboxylase in brain regions and neuronal cells. J Neurochem 96:1042–1050
Keynan O, Mirovsky Y, Dekel S, Gilad VH, Gilad GM (2010) Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial. Pain Med 11:356–368
Kim J, Yenari M, Giffard R, Cho S, Park K, Lee J (2004) Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp Neurol 189:122–130
Kreisman NR, Soliman S, Gozal D (2000) Regional differences in hypoxic depolarization and swelling in hippocampal slices. J Neurophysiol 83:1031–1038
Lee WT, Hong S, Yoon SH, Kim JH, Park KA, Seong GJ, Lee JE (2009) Neuroprotective effects of agmatine on oxygen-glucose deprived primary-cultured astrocytes and nuclear translocation of nuclear factor-kappa B. Brain Res 1281:64–70
Legido A, Valencia I, Katsetos CD, Delivoria-Papadopoulos M (2007) Neuroprotection in perinatal hypoxic-ischemic encephalopathy. Effective treatment and future perspectives. Medicina 67:543–555
Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ (1994) Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263:966–969
Li G, Regunathan S, Reis DJ (1995) Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain. Ann N Y Acad Sci 763:325–329
Liu P, Bergin DH (2009) Differential effects of i.c.v. microinfusion of agmatine on spatial working and reference memory in the rat. Neuroscience 159:951–961
Liu S, Levine SR (2008) The continued promise of neuroprotection for acute stroke treatment. J Exp Stroke Transl Med 1:1–8
Liu P, Jing Y, Collie ND, Chary S, Zhang H (2009) Memory-related changes in l-citrulline and agmatine in the rat brain. Hippocampus 19:597–602
Madai VI, Poller WC, Peters D, Berger J, Paliege K, Bernard R, Veh RW, Laube G (2011) Synaptic localisation of agmatinase in rat cerebral cortex revealed by virtual pre-embedding. Amino Acids 43(3):1399–1403
Molderings GJ, Haenisch B (2012) Agmatine (decarboxylated l-arginine): physiological role and therapeutic potential. Pharmacol Ther 133:351–365
Morris SM Jr (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 157:922–930
Noraberg J, Kristensen BW, Zimmer J (1999) Markers for neuronal degeneration in organotypic slice cultures. Brain Res Brain Res Protoc 3:278–290
Paszcuk AF, Gadotti VM, Tibola D, Quintao NL, Rodrigues AL, Calixto JB, Santos AR (2007) Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. Brain Res 1159:124–133
Piletz J, Huang M-J, Lee K (2008) Mammalian agmatinase inhibitory substance. In: Mammalian agmatinase inhibitory substance. US Patent 7347984 B2, Jackson State University, Assignee, pp 1–18
Piletz JE, Halaris A, Iqbal O, Fareed D, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, DeVane CL (2009) Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine. Intl J Health Sci 2:274–281
Regunathan S, Piletz J (2003) Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann N Y Acad Sci 1009:20–29
Reis DJ, Regunathan S (1999) Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci 881:65–80
Rice JE 3rd, Vannucci RC, Brierley JB (1981) The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 9:131–141
Salimuddin NagasakiA, Gotoh T, Isobe H, Mori M (1999) Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. Am J Physiol 277:E110–E117
Sastre M, Regunathan S, Galea E, Reis DJ (1996) Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J Neurochem 67:1761–1765
Sastre M, Galea E, Feinstein D, Reis DJ, Regunathan S (1998) Metabolism of agmatine in macrophages: modulation by lipopolysaccharide and inhibitory cytokines. Biochem J 330:1405–1409
Satriano J (2004) Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids 26:321–329
Seo S, Liu P, Leitch B (2011) Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience 192:28–36
Shopsin B (2012) The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychiatr. doi: 10.1111/j.1601-5215.2012.00675.x.
Su RB, Lu XQ, Huang Y, Liu Y, Gong ZH, Wei XL, Wu N, Li J (2008) Effects of intragastric agmatine on morphine-induced physiological dependence in beagle dogs and rhesus monkeys. Eur J Pharmacol 587:155–162
Tsuji M, Higuchi Y, Shiraishi K, Kume T, Akaike A, Hattori H (2000) Protective effect of aminoguanidine on hypoxic-ischemic brain damage and temporal profile of brain nitric oxide in neonatal rat. Pediatr Res 47:79–83
Uribe E, Salas M, Enriquez S, Orellana MS, Carvajal N (2007) Cloning and functional expression of a rodent brain cDNA encoding a novel protein with agmatinase activity, but not belonging to the arginase family. Arch Biochem Biophys 461:146–150
Wang WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY (2006) Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res 1084:210–216
Yang J, Wang WZ, Shen FM, Su DF (2005) Cardiovascular effects of agmatine within the rostral ventrolateral medulla are similar to those of clonidine in anesthetized rats. Exp Brain Res 160:467–472
Yu CG, Marcillo AE, Fairbanks CA, Wilcox GL, Yezierski RP (2000) Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. Neuroreport 11:3203–3207
Zarifkar A, Choopani S, Ghasemi R, Naghdi N, Maghsoudi AH, Maghsoudi N, Rastegar K, Moosavi M (2010) Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis. Eur J Pharmacol 634:84–88
Zhang W, Kaye D (2004) Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a time-controlled ortho-phthaldialdehyde precolumn derivatization. Anal Biochem 326:87–92
Zhu M, Iyo A, Piletz J, Regunathan S (2004) Expression of human arginine decarboxylase, the biosynthetic enzyme for agmatine. Biochim Biophys Acta 1670:156–164
Zhu MY, Wang WP, Huang J, Regunathan S (2007) Chronic treatment with glucocorticoids alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. J Neurochem 103:1811–1820
Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL (2002) Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13:387–391
Acknowledgments
This research was supported by a grant from the National Institutes of Health, R21 NS054862-1-3. For the analytical chemistry of newly-synthesized PZC, we gratefully acknowledge the Mississippi College Diffraction Facility supported by National Science Foundation grant MRI 0618148, as well as the W. M. Keck Foundation for crystallographic resources. For the brain slice procedure we thank the advice of Dr. Robert Mitchell, and for the slice hypoxia protocol we thank the advice of Dr. Rubin Mestril (both of Loyola University Medical Center, Chicago). For immunohistochemical procedures we gratefully acknowledge the advice of Dr. Rita Cowell of the University of Alabama and of Dr. Julie Fudge of the University of Rochester, NY.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Piletz, J.E., Klenotich, S., Lee, K.S. et al. Putative Agmatinase Inhibitor for Hypoxic-Ischemic New Born Brain Damage. Neurotox Res 24, 176–190 (2013). https://doi.org/10.1007/s12640-013-9376-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-013-9376-5